BRPI0816790A8 - Composições farmacêuticas contendo toxóides a e b de clostridium difficile - Google Patents

Composições farmacêuticas contendo toxóides a e b de clostridium difficile

Info

Publication number
BRPI0816790A8
BRPI0816790A8 BRPI0816790A BRPI0816790A BRPI0816790A8 BR PI0816790 A8 BRPI0816790 A8 BR PI0816790A8 BR PI0816790 A BRPI0816790 A BR PI0816790A BR PI0816790 A BRPI0816790 A BR PI0816790A BR PI0816790 A8 BRPI0816790 A8 BR PI0816790A8
Authority
BR
Brazil
Prior art keywords
clostridium difficile
pharmaceutical compositions
compositions containing
toxoids
compositions
Prior art date
Application number
BRPI0816790A
Other languages
English (en)
Portuguese (pt)
Inventor
Russell Middaugh C
Fahrner Richard
Ciarametaro Peter
Original Assignee
Sanofi Pasteur Biologics Co
Sanofi Pasteur Biologics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Biologics Co, Sanofi Pasteur Biologics Llc filed Critical Sanofi Pasteur Biologics Co
Publication of BRPI0816790A2 publication Critical patent/BRPI0816790A2/pt
Publication of BRPI0816790A8 publication Critical patent/BRPI0816790A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
BRPI0816790A 2007-09-14 2008-09-15 Composições farmacêuticas contendo toxóides a e b de clostridium difficile BRPI0816790A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97249607P 2007-09-14 2007-09-14
PCT/US2008/010767 WO2009035707A1 (en) 2007-09-14 2008-09-15 Pharmaceutical compositions containing clostridium difficile toxoids a and b

Publications (2)

Publication Number Publication Date
BRPI0816790A2 BRPI0816790A2 (pt) 2014-10-14
BRPI0816790A8 true BRPI0816790A8 (pt) 2017-05-16

Family

ID=40452372

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0816790A BRPI0816790A8 (pt) 2007-09-14 2008-09-15 Composições farmacêuticas contendo toxóides a e b de clostridium difficile

Country Status (21)

Country Link
US (3) US9320790B2 (OSRAM)
EP (3) EP2198007B1 (OSRAM)
JP (3) JP5503543B2 (OSRAM)
KR (2) KR20160005378A (OSRAM)
CN (2) CN106039299A (OSRAM)
AU (1) AU2008299885C1 (OSRAM)
BR (1) BRPI0816790A8 (OSRAM)
CA (1) CA2699435A1 (OSRAM)
CY (1) CY1119979T1 (OSRAM)
DK (1) DK2198007T3 (OSRAM)
ES (2) ES2657485T3 (OSRAM)
HR (1) HRP20180054T1 (OSRAM)
HU (1) HUE037932T2 (OSRAM)
IL (1) IL204366A (OSRAM)
MX (1) MX2010002815A (OSRAM)
NO (1) NO2198007T3 (OSRAM)
PL (1) PL2198007T3 (OSRAM)
PT (1) PT2198007T (OSRAM)
RU (1) RU2550271C2 (OSRAM)
SI (1) SI2198007T1 (OSRAM)
WO (1) WO2009035707A1 (OSRAM)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2198007B1 (en) 2007-09-14 2017-10-25 Sanofi Pasteur Biologics, LLC Pharmaceutical compositions containing clostridium difficile toxoids a and b
SMT201700124T1 (it) 2010-09-03 2017-05-08 Valneva Austria Gmbh Polipeptide isolato delle proteine di tossina a e tossina b di c. difficile e relativi usi
GB201105981D0 (en) * 2011-04-08 2011-05-18 Glaxosmithkline Biolog Sa Novel process
ES2969952T3 (es) 2011-04-22 2024-05-23 Wyeth Llc Composiciones relacionadas con una toxina mutante de Clostridium difficile y sus procedimientos
KR101135486B1 (ko) * 2011-05-25 2012-04-13 함종욱 보툴리눔 에이형 독소의 액상제품
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
EP2917238A1 (en) 2012-11-08 2015-09-16 Eleven Biotherapeutics, Inc. Il-6 antagonists and uses thereof
HRP20230359T1 (hr) 2012-12-05 2023-06-09 Glaxosmithkline Biologicals Sa Imunogeni pripravak
US10137186B2 (en) 2013-03-14 2018-11-27 Takeda Vaccines, Inc. Compositions and methods for live, attenuated alphavirus formulations
US20160030542A1 (en) * 2013-03-15 2016-02-04 Sanofi Pasteur, Inc. Toxoid, Compositions and Related Methods
JP2016516721A (ja) 2013-03-15 2016-06-09 サノフィ パストゥール インコーポレイテッド トキソイド、組成物および関連方法
CN105611942A (zh) 2013-06-14 2016-05-25 圣诺菲·帕斯图尔公司 针对艰难梭菌免疫的组合物和方法
PT3010537T (pt) 2013-06-17 2019-12-03 De Staat Der Nederlanden Vert Door De Mini Van Vws Miniie Van Volksgezondheid Welzijn En Sport Métodos para a prevenção da agregação de componentes virais
US9930893B2 (en) * 2014-02-10 2018-04-03 The Johns Hopkins University Inhibitors of DXP synthase and methods of use thereof
US11142571B2 (en) 2014-11-07 2021-10-12 Sesen Bio, Inc. IL-6 antibodies
US20180110849A1 (en) 2015-05-15 2018-04-26 Sanofi Pasteur, Inc. Methods for immunizing against clostridium difficile
BE1023343B1 (nl) * 2015-05-20 2017-02-09 Mycartis Nv Opslagbuffer
EP3419599A4 (en) 2016-02-23 2019-09-11 Sesen Bio, Inc. IL-6 ANTAGONIST FORMULATIONS AND USE THEREOF
IL265109B2 (en) 2016-09-13 2024-05-01 Allergan Inc Stabilized non-protein clostridial toxin compositions
US20210196568A1 (en) * 2018-05-21 2021-07-01 Chugai Seiyaku Kabushiki Kaisha Lyophilized formulation sealed in glass container
WO2021255690A2 (en) * 2020-06-19 2021-12-23 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof
TW202438104A (zh) * 2022-12-13 2024-10-01 美商輝瑞股份有限公司 誘發針對困難梭狀芽孢桿菌之免疫反應的免疫原性組成物和方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879218A (en) * 1982-09-13 1989-11-07 Virginia Tech Intellectual Properties, Inc. Antibody for C.difficile
US5736139A (en) * 1989-10-31 1998-04-07 Ochidian Pharmaceuticals, Inc. Treatment of Clostridium difficile induced disease
JPH03193735A (ja) 1989-12-22 1991-08-23 Shionogi & Co Ltd グリコペプチド系抗生物質の安定化組成物
ATE156019T1 (de) * 1991-10-16 1997-08-15 Schering Corp Lipophile zusammensetzungen von oligosaccharid- antibiotikasalzen
WO1994000481A1 (en) 1992-06-23 1994-01-06 Associated Synapse Biologics Pharmaceutical composition containing botulinum b complex
US5562909A (en) 1993-07-12 1996-10-08 Massachusetts Institute Of Technology Phosphazene polyelectrolytes as immunoadjuvants
US5902565A (en) * 1993-12-24 1999-05-11 Csl Limited Spray dried vaccine preparation comprising aluminium adsorbed immunogens
US5512547A (en) 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
JPH08333277A (ja) 1995-06-05 1996-12-17 Hoechst Japan Ltd ヒト血液凝固第ｘｉｉｉ因子の安定化された水性液製剤
EP0877623A1 (en) * 1995-07-07 1998-11-18 Oravax, Inc. Intranasal vaccination against gastrointestinal disease
US5932223A (en) 1996-09-26 1999-08-03 Merck & Co., Inc. Rotavirus vaccine formulations
PT892054E (pt) * 1997-06-20 2007-02-28 Intervet Int Bv Vacina de clostridium perfringens
EP1568378B1 (en) 1997-10-20 2016-03-16 Sanofi Pasteur Biologics, LLC Immunization against Clostridium difficile disease
US6969520B2 (en) * 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
EP1024826B1 (en) 1997-10-20 2005-03-16 Acambis, Inc. Passive immunization against clostridium difficile disease
US6013635A (en) * 1998-05-28 2000-01-11 Synsorb Biotech, Inc. Treatment of C. difficile toxin B associated conditions
JP2000117967A (ja) * 1998-10-16 2000-04-25 Fuji Photo Film Co Ltd インクジェット記録方法
FR2791895B1 (fr) 1999-03-23 2001-06-15 Pasteur Merieux Serums Vacc Utilisation de trehalose pour stabiliser un vaccin liquide
CN1227030C (zh) * 1999-04-19 2005-11-16 史密丝克莱恩比彻姆生物有限公司 包含皂甙和免疫刺激寡核苷酸的佐剂组合物
US6599715B1 (en) * 1999-05-12 2003-07-29 The Regents Of The University Of California Real time viability detection of bacterial spores
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
EP3192528A1 (en) 2002-02-14 2017-07-19 Chugai Seiyaku Kabushiki Kaisha Formulation of anti-il6r antibody-containing solutions comprising a sugar as a stabilizer
AU2003225057A1 (en) * 2002-04-19 2003-11-03 The Regents Of The University Of Michigan Polymer compositions that stabilize and control the release of formaldehyde-treated vaccine antigens
US20040235139A1 (en) * 2002-12-23 2004-11-25 Demain Arnold L. Clostridium difficile culture and toxin production methods
DE10333317A1 (de) * 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
JP4671864B2 (ja) 2003-10-09 2011-04-20 中外製薬株式会社 タンパク質溶液の安定化方法
KR100852824B1 (ko) 2004-07-26 2008-08-18 메르츠 파마 게엠베하 운트 코. 카가아 보툴리눔 신경독소를 포함하는 치료 조성물
EP1802349A1 (en) 2004-10-13 2007-07-04 Ilypsa, Inc. Pharmaceutical compositions comprising a toxin-binding oligosaccharide and a polymeric particle
FR2881139A1 (fr) * 2005-01-26 2006-07-28 Agronomique Inst Nat Rech Composition pour la lyophilisation de proteines
US8137677B2 (en) 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
BRPI0613001B8 (pt) 2005-10-06 2021-05-25 Allergan Inc composições farmacêuticas de toxina clostrídica estabilizada por uma não-proteína
US20090324647A1 (en) * 2005-10-11 2009-12-31 Borodic Gary E Albumin-Free Botulinum Toxin Based Pharmaceutical Compositions Containing a Hyaluronidase and Methods of Use
CA2668834C (en) 2006-11-07 2016-10-11 Sanofi Pasteur Biologics Co. Stabilization of vaccines by lyophilization
EP2198007B1 (en) 2007-09-14 2017-10-25 Sanofi Pasteur Biologics, LLC Pharmaceutical compositions containing clostridium difficile toxoids a and b
US20110243991A1 (en) * 2008-12-03 2011-10-06 Boehringer Ingelheim Vetmedica Gmbh Process for production of vaccines

Also Published As

Publication number Publication date
EP3124044B8 (en) 2025-01-22
EP4537849A2 (en) 2025-04-16
JP2010539172A (ja) 2010-12-16
KR101679812B1 (ko) 2016-11-28
PT2198007T (pt) 2018-01-29
JP2014055174A (ja) 2014-03-27
CY1119979T1 (el) 2018-12-12
US10639362B2 (en) 2020-05-05
CN101855336A (zh) 2010-10-06
RU2010114730A (ru) 2011-10-20
BRPI0816790A2 (pt) 2014-10-14
HUE037932T2 (hu) 2018-09-28
MX2010002815A (es) 2010-07-30
EP3124044A1 (en) 2017-02-01
US9687541B2 (en) 2017-06-27
KR20100075912A (ko) 2010-07-05
WO2009035707A9 (en) 2010-06-10
JP6258674B2 (ja) 2018-01-10
US20180000920A1 (en) 2018-01-04
JP2017052773A (ja) 2017-03-16
JP5503543B2 (ja) 2014-05-28
SI2198007T1 (en) 2018-04-30
ES2657485T3 (es) 2018-03-05
KR20160005378A (ko) 2016-01-14
RU2550271C2 (ru) 2015-05-10
CN106039299A (zh) 2016-10-26
HRP20180054T1 (hr) 2018-02-09
CA2699435A1 (en) 2009-03-19
IL204366A (en) 2013-02-28
EP3124044B1 (en) 2024-12-18
PL2198007T3 (pl) 2018-03-30
EP2198007B1 (en) 2017-10-25
US20110045025A1 (en) 2011-02-24
AU2008299885C1 (en) 2015-06-25
EP3124044C0 (en) 2024-12-18
US9320790B2 (en) 2016-04-26
ES3001561T3 (en) 2025-03-05
US20160317640A1 (en) 2016-11-03
CN101855336B (zh) 2019-07-30
AU2008299885A1 (en) 2009-03-19
EP4537849A3 (en) 2025-07-09
AU2008299885B2 (en) 2014-12-11
WO2009035707A1 (en) 2009-03-19
EP2198007A4 (en) 2012-03-07
EP2198007A1 (en) 2010-06-23
NO2198007T3 (OSRAM) 2018-03-24
DK2198007T3 (en) 2018-01-15

Similar Documents

Publication Publication Date Title
EP4537849A3 (en) Pharmaceutical compositions containing clostridium difficile toxoids a and b
BR112017013661A8 (pt) Conjugado derivado de antraciclina (pnu), conjugado de fármaco-proteína de ligação (bpdc), método para a produção de um conjugado de fármaco-proteína de ligação (bpdc), uso de um conjugado de proteína de ligação-fármaco (bpdc) e composição farmacêutica
BR112018077266A2 (pt) composições compreendendo cepas bacterianas
TNSN07387A1 (en) C.perfringens alpha toxoid vaccine
MA43518B1 (fr) 3-azabicyclo[3.1.0]hexanes substitués servant d'inhibiteurs de cétohexokinase
BR112015022095A8 (pt) composição farmacêutica, método de fabricação, composição eutética e uso de composições contendo hcl ciclobenzabrina e manitol
MA47664A1 (fr) Anticorps anti-c10orf54 et leurs utilisations
EP4414376A3 (en) Novel depsipeptide and uses thereof
CL2016001235A1 (es) Cepa bacteriana aislada del genero burkholderia y metabolitos plaguicidas derivados-formulaciones y usos (divisional solicitud 467-2014).
BR112014014410A2 (pt) composições e métodos que compreendem uma variante de enzima lipolítica
NZ726746A (en) Stable cannabinoid formulations
BR112015008419A2 (pt) composição imunogênica, e, vacina
BR112012019997A2 (pt) composições de cuidado oral
MX2017015879A (es) Composiciones de hidroxipropil beta-ciclodextrina y metodos.
EA201001479A1 (ru) Вакцина
EP3878445A3 (en) Acamprosate formulations, methods of using the same, and combinations comprising the same
BR112015023332A2 (pt) Toxóide, composições e método relacionados
BR112014013876A2 (pt) vacina à base de toxina de clostridium difficile
IN2014DN09791A (OSRAM)
BR112018012618A2 (pt) composições da nano emulsão de fluorocarbonos e métodos de preparação e uso dos mesmos
BR112017009510A2 (pt) composições compreendendo ciclosporina
MX364946B (es) Sistema adyuvante mejorado para la administración de vacunas orales.
BR112019004303A2 (pt) composição de conjugados multivalentes de polissacarídeo capsular pneumocócico-proteína portadora e uso da mesma
BR112013019924A8 (pt) Composições para cuidado oral
BR112015030331A2 (pt) derivados de succinato

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B25D Requested change of name of applicant approved

Owner name: SANOFI PASTEUR BIOLOGICS, LLC (US)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 12A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2598 DE 20-10-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]